← Back to patent-cliff list
达格列净丙二醇一水化物
Tier C — Watch / tradeDapagliflozin Propanediol Monohydrate
百时美施贵宝
Originator
2012
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：SGLT2
Brand：Edistride、Forxiga、Farxiga
Indications (approved)：慢性肾功能不全、心脏衰竭、肾脏疾病、一型糖尿病、二型糖尿病
Regional status
US
批准上市
2014-01-08
EU
批准上市
2012-11-11
China
批准上市
2017-03-10
Japan
批准上市
2014-03-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dapagliflozin Propanediol Monohydrate?
Approved indications include: 慢性肾功能不全, 心脏衰竭, 肾脏疾病, 一型糖尿病, 二型糖尿病.
When does the Dapagliflozin Propanediol Monohydrate patent expire?
No public expiry year is available for Dapagliflozin Propanediol Monohydrate yet; this page updates once verified.
How do I get a quote for Dapagliflozin Propanediol Monohydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25